Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Coreg · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Carvedilol Tablets 12.5 mg |
| 2 | ACTIVE_COMPARATOR | Coreg® Tablets 12.5 mg |
| Name | Type | Description |
|---|---|---|
| Carvedilol Tablets 12.5 mg | DRUG | 12.5mg, single dose fed |
| Coreg® Tablets 12.5 mg | DRUG | 12.5mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the ev...
Coreg is a small molecule drug being developed by Viatris Inc. (VTRS) for use in healthy volunteers. It is currently in Phase 1 clinical development, with studies evaluating the drug in healthy individuals. Coreg is not approved for any indication and remains investigational.
Coreg is developed by Viatris Inc., a pharmaceutical company traded on the NASDAQ under the ticker symbol VTRS. The company is conducting Phase 1 clinical trials to evaluate the drug in healthy volunteers.
Coreg is in Phase 1 clinical development. Two Phase 1 trials have been completed, both enrolling healthy volunteers in the United States. The drug is investigational and has not been approved by regulatory authorities.
Coreg has two completed Phase 1 trials: NCT00648622, a fed study comparing carvedilol tablets 12.5 mg to Coreg tablets 12.5 mg, and NCT00650416, a fasting study with the same comparison. Both enrolled 50 healthy volunteers each in the United States.
Coreg is a brand name for carvedilol. The clinical trials for Coreg compare carvedilol tablets to Coreg tablets, indicating that carvedilol is the active ingredient in Coreg. Both are being studied in healthy volunteers.